Press Release

United Kingdom Cell & Gene Therapy Cold Chain Logistics Market to be Dominated by Transportation Type Service Segment through 2028

Increasing demand for cell and gene therapies, development of advanced cold chain technologies and solutions, and presence of a strong research and innovation ecosystem are factors that drives United Kingdom cell & gene therapy cold chain logistics market in the forecast period 2024-2028


According to TechSci Research report,
United Kingdom Cell & Gene Therapy Cold Chain Logistics Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028”, United Kingdom Cell & Gene Therapy Cold Chain Logistics Market Size is anticipated to increase at a substantial rate in the forecast period.  The supportive regulatory environment and government initiatives are expected to propel the growth of the United Kingdom's cell and gene therapy cold chain logistics market. These initiatives have helped to position the United Kingdom as a global leader in the cell and gene therapy industry and have provided a clear path to market for these therapies. As the sector continues to grow, it is expected to see further investment and innovation in cold chain logistics technologies and solutions, enabling the safe and efficient delivery of these life-changing therapies to patients. Moreover, the use of advanced technologies such as adoption of automation and robotics, real-time monitoring and tracking, cloud-based logistics management systems, blockchain technology, and AI and ML is enabling logistics providers to improve their efficiency, accuracy, and safety of transporting these therapies is transforming the United Kingdom's cell and gene therapy cold chain logistics market. As the demand for cell and gene therapies continues to grow, it is expected that the further technological advancements and innovations in the logistics processes will happen to ensure the safe and efficient transportation of these life-changing therapies to patients in need.

At the identical time, the cell & gene therapy cold chain logistics market in United Kingdom faces several challenges such as maintaining the cold chain, lack of standardization, transportation costs, and need of skilled worker. The transportation of cell and gene therapies is costly due to the specialized equipment and requirements needed to maintain the cold chain. The cost of transportation can be a significant challenge, especially for small companies or organizations with limited resources. Beside this, there is a lack of standardization in the industry, making it challenging for logistics providers to develop consistent processes for transporting cell and gene therapies. The lack of standardization can result in inconsistencies in transportation processes, increasing the risk of temperature deviations or other issues.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on the "United Kingdom Cell and Gene Therapy Cold Chain Logistics Market.”


United Kingdom Cell & Gene Therapy Cold Chain Logistics market is segmented based on component, services offered, mode of transportation, holding temperature range, end user, and region.

Based on the service offered, the market is divided into transportation, storage, and packaging.  The transportation segment is expected to hold the largest market share in the forecast period due to the high demand for transporting cell and gene therapy products across different the world. These products require strict temperature control and monitoring to ensure their quality and efficacy during transportation from hospital or research institution.

Based on the end user, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others. The pharmaceutical & biotechnology companies’ segment is expected to hold the largest market share in the forecast period due to the high demand for these therapies from patients with chronic and rare diseases. Pharmaceutical & biotechnology companies are investing heavily in research and development of cell and gene therapies, as well as in manufacturing and distribution facilities that require cold chain logistics. These companies also have the expertise and resources to ensure the quality and safety of these therapies throughout the supply chain. Therefore, they are the leading end users of Cell & Gene Therapy Cold Chain Logistics services.

Major companies operating in the United Kingdom Cell & Gene Therapy Cold Chain Logistics market are:

  • Atelerix Ltd.
  • Life Science Group Ltd (LSG)
  • Arvato Group
  • DGP Intelius Ltd.
  • QuickSTAT (A Kuehne + Nagel Company)
  • BIOCAIR
  • TrakCel
  • Cryoport UK Limited
  • Patheon UK Limited (Thermo Fischer Scientific UK)
  • Catalent UK



Download Free Sample Report
Customers can also request for 10% free customization on this report. 


“United Kingdom cell and gene therapy cold chain logistics market is evolving rapidly due to the increasing demand for these therapies. Several trends are driving the market growth, including the adoption of automation and robotics in logistics processes, real-time monitoring and tracking technologies, cloud-based logistics management systems, blockchain technology, and artificial intelligence and machine learning. These advanced technologies enable logistics providers to optimize their processes, reduce transportation costs, and ensure the safety and efficiency of transporting cell and gene therapies. However, there are still several challenges facing the industry, such as maintaining the cold chain, transportation costs, regulatory compliance, limited infrastructure, and lack of standardization. To overcome these such challenges, logistics providers must invest in advanced technologies and innovative solutions to ensure the safe and efficient transportation of cell and gene therapies to patients.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.

United Kingdom Cell & Gene Therapy Cold Chain Logistics Market, By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits Others {Shipment Containers, Reusable Boxes, etc.}), By Services Offered (Transportation, Storage, Packaging), By Mode of Transportation (Air, Ground, Water), By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others {Deep Freezers, Dry Ice, etc.}), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, Competition, Forecast & Opportunities, 2018-2028F, has evaluated the future growth potential of United Kingdom cell & gene therapy cold chain logistics market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United Kingdom cell & gene therapy cold chain logistics market.”

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]
Website: https://www.techsciresearch.com

Relevant News